Recognizing the diverse roles of Galectin-1 could potentially unlock new therapeutic avenues to combat this aggressive cancer, especially given its impact on pancreatic cancer cell migration, fibrosis, and the epithelial–mesenchymal transition (EMT) [81]. This evidence concerns the gene LGALS1 and familial pancreatic carcinoma.